Neurovascular bundle

Global Atherectomy Devices Market Report 2023-2030: Industry Trends, Growth, Share, Outlook, Impact of Inflation, Opportunities, Company Analysis - ResearchAndMarkets.com

Retrieved on: 
Monday, January 8, 2024

The "Atherectomy Devices Market, Size, Global Forecast 2023-2030, Industry Trends, Growth, Share, Outlook, Impact of Inflation, Opportunity Company Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Atherectomy Devices Market, Size, Global Forecast 2023-2030, Industry Trends, Growth, Share, Outlook, Impact of Inflation, Opportunity Company Analysis" report has been added to ResearchAndMarkets.com's offering.
  • Atherectomy devices are minimally invasive medical devices that are used to eliminate plaque build-up from the partitions of arteries.
  • By Product Type, Global Atherectomy Devices Market is divided into Directional Atherectomy, Rotational Atherectomy, Orbital Atherectomy and Laser Atherectomy.
  • Hospitals are poised to maintain their stronghold with the very best market proportion in the Atherectomy Devices Market.

Unlocking Growth Opportunities: Explore the Neurovascular Thrombectomy Devices Market for Strategic Planning and Investment Insights - ResearchAndMarkets.com

Retrieved on: 
Tuesday, November 14, 2023

The model discusses in detail the impact of COVID-19 on Neurovascular Thrombectomy Devices market for the year 2020 and beyond.

Key Points: 
  • The model discusses in detail the impact of COVID-19 on Neurovascular Thrombectomy Devices market for the year 2020 and beyond.
  • Neurovascular thrombectomy devices are used for the removal of a blood clot in the neurovascular vessels during an acute ischemic stroke.
  • Key Inclusions of the market model are:
    Currently marketed Neurovascular Thrombectomy Devices and evolving competitive landscape:
    Insightful review of the key industry trends.
  • Annualized total Neurovascular Thrombectomy Devices market revenue by segment and market outlooks from 2015-2033.

Alzheimer's Drug Discovery Foundation and Harrington Discovery Institute Center for Brain Health Medicines Invite Proposals for 2023 ADDF-Harrington Scholar Award

Retrieved on: 
Monday, April 3, 2023

CLEVELAND, April 3, 2023 /PRNewswire/ -- Harrington Discovery Institute Center for Brain Health Medicines at University Hospitals and the Alzheimer's Drug Discovery Foundation (ADDF) announce a joint request for proposal for the 2023 ADDF-Harrington Scholar Award. The ADDF-Harrington Scholar Award is designed to accelerate the translation of innovative research that could treat, prevent, slow, or reverse Alzheimer's disease or related dementias.

Key Points: 
  • CLEVELAND, April 3, 2023 /PRNewswire/ -- Harrington Discovery Institute Center for Brain Health Medicines at University Hospitals and the Alzheimer's Drug Discovery Foundation (ADDF) announce a joint request for proposal for the 2023 ADDF-Harrington Scholar Award .
  • The ADDF-Harrington Scholar Award is designed to accelerate the translation of innovative research that could treat, prevent, slow, or reverse Alzheimer's disease or related dementias.
  • Researchers working on drug development programs that are relevant to, but not presently focused on, the Alzheimer's field are strongly encouraged to apply.
  • This award provides a combination of financial support and expert drug development guidance to provide optimal support for moving research beyond the bench to the bedside.

Endogenex™ Appoints Medical Device Executive, Stacey Pugh, Chief Executive Officer

Retrieved on: 
Thursday, March 23, 2023

MINNEAPOLIS, March 23, 2023 /PRNewswire/ -- Endogenex, Inc., a clinical stage medical device company, is proud to announce the addition of Stacey Pugh as Chief Executive Officer (CEO). In this role Stacey will lead the organization as it expands its clinical initiatives evaluating the novel ReCET™ Procedure for the treatment of Type 2 Diabetes.

Key Points: 
  • MINNEAPOLIS, March 23, 2023 /PRNewswire/ -- Endogenex, Inc., a clinical stage medical device company, is proud to announce the addition of Stacey Pugh as Chief Executive Officer (CEO).
  • "We are thrilled to have Stacey join the Endogenex team," said James Eadie MD, Endogenex Board Member and Managing Director, Santé.
  • "Stacy is a proven leader with extensive experience in running global clinical and commercial stage medical device organizations.
  • She spent the first half of her medical device career leading clinical and medical affairs teams at Medtronic, Covidien, and Kinetic Concepts.

Shape Memory Medical Announces First Patient Treated in the EMBO-Post Market Surveillance Registry in Germany

Retrieved on: 
Wednesday, February 22, 2023

Shape Memory Medical Inc., developer of shape memory polymer for peripheral and neurovascular markets, announced the first patient treated in Germany as part of the EMBO-Post Market Surveillance Registry, the Company’s prospective, multicenter, registry study of its IMPEDE and IMPEDE-FX Embolization Plugs when used for peripheral vascular embolization.

Key Points: 
  • Shape Memory Medical Inc., developer of shape memory polymer for peripheral and neurovascular markets, announced the first patient treated in Germany as part of the EMBO-Post Market Surveillance Registry, the Company’s prospective, multicenter, registry study of its IMPEDE and IMPEDE-FX Embolization Plugs when used for peripheral vascular embolization.
  • Ted Ruppel, President and Chief Executive Officer of Shape Memory Medical Inc. said, “We would like to congratulate Professor Richter and the clinical study team at Klinikum Stuttgart for the first EMBO-PMS case in Germany.
  • “We are pleased to participate in this important study and look forward to the follow-up from our treated patients,” said Professor Richter, Principal Investigator for EMBO-Post Market Surveillance German Registry.
  • Shape Memory Medical Inc. is dedicated to developing innovative therapeutic solutions with its proprietary shape memory polymers.

Align Technology Appoints Karim Boussebaa, EVP and MD of iTero Scanner and Services Business—Yuval Shaked to Leave Align End of 2023

Retrieved on: 
Wednesday, February 8, 2023

He will remain with Align and continue as a member of Align Technology President and CEO Joe Hogan’s staff supporting strategic initiatives and programs through 2023.

Key Points: 
  • He will remain with Align and continue as a member of Align Technology President and CEO Joe Hogan’s staff supporting strategic initiatives and programs through 2023.
  • Mr. Shaked will transition his role to Karim Boussebaa, who will join Align on February 27 and assume the role of executive vice president and managing director of iTero scanner and services, effective immediately.
  • I want to thank Yuval for his tremendous contributions and leadership of the iTero scanner and services business.
  • Commenting on Mr. Boussebaa’s new position, Align Technology President and CEO Joe Hogan said, “I am very excited to have Karim join Align.

Mentice AB (publ) receives an order of USD 540,000 for simulation solutions from Corewell Health, Grand Rapids, Michigan, USA

Retrieved on: 
Friday, December 30, 2022

GOTHENBURG, Sweden, Dec. 30, 2022 /PRNewswire/ -- Mentice AB (publ), Gothenburg, a world leader in simulation solutions for image-guided interventional therapies, announced today that Corewell Health, Grand Rapids, Michigan USA, has signed an agreement to acquire Mentice VIST® simulation solutions for an order of USD 540,000.

Key Points: 
  • GOTHENBURG, Sweden, Dec. 30, 2022 /PRNewswire/ -- Mentice AB (publ), Gothenburg, a world leader in simulation solutions for image-guided interventional therapies, announced today that Corewell Health, Grand Rapids, Michigan USA, has signed an agreement to acquire Mentice VIST® simulation solutions for an order of USD 540,000.
  • Mentice (STO: MNTC) is the world leader in proficiency based simulation solutions for image guided interventional therapies.
  • Mentice solutions are scientifically validated and have been specifically developed for healthcare providers and the medical device industry.
  • Learn more about the features and benefits of Mentice solutions at: www.mentice.com
    This information is information that Mentice AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation.

Mentice AB (publ) receives an order of USD 540,000 for simulation solutions from Corewell Health, Grand Rapids, Michigan, USA

Retrieved on: 
Friday, December 30, 2022

GOTHENBURG, Sweden, Dec. 30, 2022 /PRNewswire/ -- Mentice AB (publ), Gothenburg, a world leader in simulation solutions for image-guided interventional therapies, announced today that Corewell Health, Grand Rapids, Michigan USA, has signed an agreement to acquire Mentice VIST® simulation solutions for an order of USD 540,000.

Key Points: 
  • GOTHENBURG, Sweden, Dec. 30, 2022 /PRNewswire/ -- Mentice AB (publ), Gothenburg, a world leader in simulation solutions for image-guided interventional therapies, announced today that Corewell Health, Grand Rapids, Michigan USA, has signed an agreement to acquire Mentice VIST® simulation solutions for an order of USD 540,000.
  • Mentice (STO: MNTC) is the world leader in proficiency based simulation solutions for image guided interventional therapies.
  • Mentice solutions are scientifically validated and have been specifically developed for healthcare providers and the medical device industry.
  • Learn more about the features and benefits of Mentice solutions at: www.mentice.com
    This information is information that Mentice AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation.

Mentice AB (publ) receives an order of 1,1 million USD for simulation solutions from Beijing Huanya Zhitong on behalf of the Chinese Medical Education Association.

Retrieved on: 
Monday, December 19, 2022

GOTHENBURG, Sweden, Dec. 19, 2022 /PRNewswire/ -- Mentice AB (publ), Gothenburg, a world leader in simulation solutions for image-guided interventional therapies, announced today that Beijing Huanya Zhitong, Beijing, China, has signed an agreement to acquire Mentice VIST® simulation solutions for an order of 1,1 million USD.

Key Points: 
  • GOTHENBURG, Sweden, Dec. 19, 2022 /PRNewswire/ -- Mentice AB (publ), Gothenburg, a world leader in simulation solutions for image-guided interventional therapies, announced today that Beijing Huanya Zhitong, Beijing, China, has signed an agreement to acquire Mentice VIST® simulation solutions for an order of 1,1 million USD.
  • Mentice is the world leader in virtual and physical simulation solutions for Image-Guided Interventional therapies.
  • Our solutions help healthcare professionals acquire, retain, and enhance their procedural skills, driving improved productivity and outcomes.
  • Mentice's solutions are scientifically validated and specifically developed for healthcare providers and the medical device industry.

Mentice AB (publ) receives an order of 1,1 million USD for simulation solutions from Beijing Huanya Zhitong on behalf of the Chinese Medical Education Association.

Retrieved on: 
Monday, December 19, 2022

GOTHENBURG, Sweden, Dec. 19, 2022 /PRNewswire/ -- Mentice AB (publ), Gothenburg, a world leader in simulation solutions for image-guided interventional therapies, announced today that Beijing Huanya Zhitong, Beijing, China, has signed an agreement to acquire Mentice VIST® simulation solutions for an order of 1,1 million USD.

Key Points: 
  • GOTHENBURG, Sweden, Dec. 19, 2022 /PRNewswire/ -- Mentice AB (publ), Gothenburg, a world leader in simulation solutions for image-guided interventional therapies, announced today that Beijing Huanya Zhitong, Beijing, China, has signed an agreement to acquire Mentice VIST® simulation solutions for an order of 1,1 million USD.
  • Mentice is the world leader in virtual and physical simulation solutions for Image-Guided Interventional therapies.
  • Our solutions help healthcare professionals acquire, retain, and enhance their procedural skills, driving improved productivity and outcomes.
  • Mentice's solutions are scientifically validated and specifically developed for healthcare providers and the medical device industry.